Ovid Therapeutics (OVID)
Develops targeted small molecules for neurological disorders involving neuronal hyperexcitability.
$2.56
vs last close−0.21 (−7.43%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
estimated · in 49 days
EPS estimate
−$0.08
Revenue estimate
$17.8K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.13−$0.14−$0.06−$0.17$0.06−$0.12−$0.08Pending
Estimate−$0.16−$0.14−$0.16−$0.15−$0.10−$0.12−$0.12−$0.08
Surprise+18.8%0.0%+62.5%−13.3%+160.0%0.0%+30.4%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$76.0K$130.0K$6.3M$132.0K$718.0K—$733.0KPending
Estimate$100.0K$42.5K$61.3K$62.6K$78.3K$56.7K$21.4K$17.8K
Surprise−24.0%+205.9%+10,126.6%+110.9%+817.6%—+3,320.6%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.09 | — | — |
| Sep 2028 | −$0.08 | — | — |
| Jun 2028 | −$0.08 | — | — |
| Mar 2028 | −$0.08 | — | — |
| Dec 2027 | −$0.11 | — | — |
| Sep 2027 | −$0.10 | — | — |
| Jun 2027 | −$0.09 | — | — |
| Mar 2027 | −$0.09 | — | — |
| Dec 2026 | −$0.09 | — | — |
| Nov 2026 | −$0.08 | — | — |
| Aug 2026 | −$0.12 | −$0.08 | +30.4% |
| May 2026 | −$0.12 | −$0.12 | 0.0% |
| Mar 2026 | −$0.10 | $0.06 | +160.0% |
| Nov 2025 | −$0.15 | −$0.17 | −13.3% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| Jun 2017 | |||
| May 2017 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.09 | — | — | $718.0K | — | — | — |
| Sep 2028 | −$0.08 | — | — | $132.0K | — | — | — |
| Jun 2028 | −$0.08 | — | — | $733.0K | — | — | — |
| Mar 2028 | −$0.08 | — | — | $130.0K | — | — | — |
| Dec 2027 | −$0.11 | — | — | $204.5K | — | — | — |
| Sep 2027 | −$0.10 | — | — | $58.0K | — | — | — |
| Jun 2027 | −$0.09 | — | — | $208.3K | — | — | — |
| Mar 2027 | −$0.09 | — | — | $33.3K | — | — | — |
| Dec 2026 | −$0.09 | — | — | $98.1K | — | — | — |
| Nov 11, 2026 | −$0.08 | — | — | $17.8K | — | — | — |
| Aug 13, 2026 | −$0.12 | −$0.08 | +30.4% | $21.4K | $733.0K | +3,320.6% | +6.9% |
| May 12, 2026 | −$0.12 | −$0.12 | 0.0% | $56.7K | — | — | +2.9% |
| Mar 18, 2026 | −$0.10 | $0.06 | +160.0% | $78.3K | $718.0K | +817.6% | +14.4% |
| Nov 12, 2025 | −$0.15 | −$0.17 | −13.3% | $62.6K | $132.0K | +110.9% | −2.2% |
| Aug 13, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 11, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 14, 2024 | |||||||
| Mar 8, 2024 | |||||||
| Nov 3, 2023 | |||||||
| Aug 4, 2023 | |||||||
| May 5, 2023 | |||||||
| Mar 13, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 15, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 16, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 15, 2021 | |||||||
| Nov 12, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 11, 2020 | |||||||
| Nov 8, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 7, 2019 | |||||||
| Mar 7, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 8, 2018 | |||||||
| Mar 29, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 10, 2017 | |||||||
| Jun 13, 2017 | |||||||
| May 5, 2017 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 |